(firstQuint)An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

 To evaluate the potential of DSXS to suppress HPA axis function in patients with mild to moderate plaque psoriasis.

 To evaluate the efficacy parameters and adverse event (AE) profile of DSXS administered to patients with mild to moderate plaque psoriasis.

.

 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression@highlight

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS (Taro Pharmaceuticals U.

S.

A.

, Inc.

) in Patients with Plaque Psoriasis